212 related articles for article (PubMed ID: 17511440)
1. Linear TMC-95-based proteasome inhibitors.
Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J
J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440
[TBL] [Abstract][Full Text] [Related]
2. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
Groll M; Götz M; Kaiser M; Weyher E; Moroder L
Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
[TBL] [Abstract][Full Text] [Related]
3. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.
Kaiser M; Milbradt AG; Siciliano C; Assfalg-Machleidt I; Machleidt W; Groll M; Renner C; Moroder L
Chem Biodivers; 2004 Jan; 1(1):161-73. PubMed ID: 17191784
[TBL] [Abstract][Full Text] [Related]
4. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
[TBL] [Abstract][Full Text] [Related]
5. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.
Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M
ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286
[No Abstract] [Full Text] [Related]
6. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of FAJANU: a de novo C(2) symmetric cyclopeptide family.
Garcia-Martin F; Cruz LJ; Rodriguez-Mias RA; Giralt E; Albericio F
J Med Chem; 2008 Jun; 51(11):3194-202. PubMed ID: 18461923
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, conformational analysis, and cytotoxicity of new analogues of the natural cyclodepsipeptide jaspamide.
Terracciano S; Bruno I; Bifulco G; Copper JE; Smith CD; Gomez-Paloma L; Riccio R
J Nat Prod; 2004 Aug; 67(8):1325-31. PubMed ID: 15332850
[TBL] [Abstract][Full Text] [Related]
9. Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Vivier M; Jarrousse AS; Bouchon B; Galmier MJ; Auzeloux P; Sauzieres J; Madelmont JC
J Med Chem; 2005 Oct; 48(21):6731-40. PubMed ID: 16220988
[TBL] [Abstract][Full Text] [Related]
10. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
11. Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors.
Baldisserotto A; Ferretti V; Destro F; Franceschini C; Marastoni M; Gavioli R; Tomatis R
J Med Chem; 2010 Sep; 53(17):6511-5. PubMed ID: 20687609
[TBL] [Abstract][Full Text] [Related]
12. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
[TBL] [Abstract][Full Text] [Related]
13. Constrained derivatives of stylostatin 1. 1. Synthesis and biological evaluation as potential anticancer agents.
Forns P; Piró J; Cuevas C; García M; Rubiralta M; Giralt E; Diez A
J Med Chem; 2003 Dec; 46(26):5825-33. PubMed ID: 14667235
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity of mechercharmycin A analogues.
Hernández D; Altuna M; Cuevas C; Aligué R; Albericio F; Alvarez M
J Med Chem; 2008 Sep; 51(18):5722-30. PubMed ID: 18763756
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological characterization of argyrin F.
Bülow L; Nickeleit I; Girbig AK; Brodmann T; Rentsch A; Eggert U; Sasse F; Steinmetz H; Frank R; Carlomagno T; Malek NP; Kalesse M
ChemMedChem; 2010 Jun; 5(6):832-6. PubMed ID: 20358576
[No Abstract] [Full Text] [Related]
16. Vinyl ester-based cyclic peptide proteasome inhibitors.
Baldisserotto A; Marastoni M; Fiorini S; Pretto L; Ferretti V; Gavioli R; Tomatis R
Bioorg Med Chem Lett; 2008 Mar; 18(6):1849-54. PubMed ID: 18294845
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
[TBL] [Abstract][Full Text] [Related]
18. Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jul; 47(14):3697-9. PubMed ID: 15214797
[TBL] [Abstract][Full Text] [Related]
19. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines.
Anshu A; Thomas S; Agarwal P; Ibarra-Rivera TR; Pirrung MC; Schönthal AH
Biochem Pharmacol; 2011 Sep; 82(6):600-9. PubMed ID: 21736873
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies of targeting ligands against breast cancer cells.
Yao N; Xiao W; Meza L; Tseng H; Chuck M; Lam KS
J Med Chem; 2009 Nov; 52(21):6744-51. PubMed ID: 19835381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
